BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research
BRANFORD, Connecticut and SHENZHEN, China, May 15, 2012 /PRNewswire/ –
BGI, one of the world’s largest genomics organizations, announced today that a new
Roche GS FLX+ System has been successfully installed at its facility in Shenzhen, China.
The goal is to complement the existing array of short read sequencing technologies and
enhance BGI’s long read sequencing capability.
The GS FLX+ System, developed by 454 Life Sciences, a Roche Company, features the
unique combination of long reads, exceptional accuracy and high-throughput, making the
system well suited for larger genome projects. “We’re excited that BGI has implemented our
GS FLX+ System in their Shenzhen facility,” said Thomas Schinecker, President of 454 Life
Sciences. “This again demonstrates the continued importance of the GS FLX+ platform and
its utility as a powerful replacement for Sanger sequencing applications.”
“We are very pleased to have Roche’s GS FLX+ System,” said, Meifang Tang, Director of
NGS Department at BGI, “So far, the system has been operated successfully with a stable
performance. We can achieve the read lengths up to 1000 bp reads in our laboratory. With
the implement of this system, we hope assemblies will be greatly improved with fewer gaps,
longer contigs and scaffolds in de novo genomics and transcriptomic research.”
Roche and BGI have been working closely together over the years. They have made great
collaborative efforts to develop methodologies and tools to assist scientists pursuing
genomics research. Last November, Roche NimbleGen, Inc. and BGI developed a Major
Histocompatibility Complex (MHC) region capture technology that will help advance research
and development of new medicines for human diseases. “In the future, I hope we can
cooperate even more closely, and make more breakthroughs in life science,” added Tang.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare
with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company with truly differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare
strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. In 2011, Roche had
over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group
posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned
member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For
more information: http://www.roche.com.
BGI was founded in Beijing, China, in 1999 with the mission to become a premier
scientific partner for the global research community. The goal of BGI is to make
leading-edge genomic science highly accessible, which it achieves through its investment
in infrastructure, leveraging the best available technology, economies of scale, and
expert bioinformatics resources. BGI, and its affiliates, BGI Americas, headquartered in
Cambridge, MA, and BGI Europe, headquartered in Copenhagen, Denmark, have established
partnerships and collaborations with leading academic and government research institutions
as well as global biotechnology and pharmaceutical companies, supporting a variety of
disease, agricultural, environmental, and related applications.
BGI has a proven track record of excellence, delivering results with high efficiency
and accuracy for innovative, high-profile research: research that has generated over 170
publications in top-tier journals such as Nature and Science. BGI’s many accomplishments
include: sequencing one percent of the human genome for the International Human Genome
Project, contributing 10 percent to the International Human HapMap Project, carrying out
research to combat SARS and German deadly E. coli, playing a key role in the Sino-British
Chicken Genome Project, and completing the sequence of the rice genome, the silkworm
genome, the first Asian diploid genome, the potato genome, and, more recently, have
sequenced the human Gut Metagenome, and a significant proportion of the genomes for the
1000 Genomes Project. For more information about BGI, please visit http://www.genomics.cn
ft\Windows\Temporary Internet Files\Content.Outlook\Local Settings\Temporary Internet
For life science research only. Not for use in diagnostic procedures.
454, 454 LIFE SCIENCES, 454 SEQUENCING, GS FLX and NIMBLEGEN are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
For further information please contact: Roche Diagnostics Dr. Burkhard Ziebolz Phone: +49 8856 604830 Email: firstname.lastname@example.org 454 Life Sciences Corporation, a Roche Company Katie Montgomery Phone: 203-871-2300 Email: email@example.com BGI Bicheng Yang, Public Communication Officer +86-755-82639701 firstname.lastname@example.org
SOURCE Roche Diagnostics GmbH